CMF (chemotherapy): Difference between revisions
CSV import |
No edit summary |
||
| Line 58: | Line 58: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Revision as of 16:50, 22 March 2025
| Pronunciation | |
|---|---|
| Other names | |
| Medical specialty | oncology |
| Uses | |
| Complications | |
| Approach | |
| Types | |
| Recovery time | |
| Other options | |
| Frequency |
Cyclophosphamide Methotrexate Fluorouracil (CMF) is a commonly used regimen of breast cancer chemotherapy that combines three anti-cancer agents: cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU).<ref name="pmid18306034">,
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944), Breast Cancer Res. Treat., 2008, Vol. 113(Issue: 3), pp. 479–90, DOI: 10.1007/s10549-008-9943-2, PMID: 18306034, PMC: 4217205,</ref>
While it is no longer considered the most efficient all-around chemotherapy, it retains a great importance in the treatment of elderly patients with luminal cancers and may become important for the treatment of estrogen receptor negative androgen receptor positive luminal (GATA3 expressing) breast cancer.
The regimen was designed in order to mimic the highly successful regimen developed to treat Hodgkin's lymphoma.<ref name="classic">,
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions, Annals of Oncology, 2002, Vol. 13(Issue: 3), pp. 416–421, DOI: 10.1093/annonc/mdf051, PMID: 11996473, Full text,</ref>
Treatment
The treatment is administrated over a four-week cycle. On days 1 and 8 methotraxate and 5-FU are given as injections. Cyclophosphamide may be also administered intravenously in conjunction with these drugs, or may be taken as an oral tablet, taken once each day for the first 14 days of each cycle.<ref name=breakthrough>
CMF (cyclophosphamide, methotrexate and 5-fluorouracil)(link). {{{website}}}. Breakthrough Breast Cancer.
UK.
</ref>
Side effects
Side effects of CMF treatment include:<ref name=breakthrough/>
References
<references group="" responsive="1"></references>
